How to verify a peptide provider: a 10-point checklist
To verify a peptide provider as of October 15, 2026, confirm four things: a named clinician licensed in your state, a named pharmacy whose licence you can look up, a substance that is FDA-approved or in FDA’s Category 1, and no “research use only” language anywhere. A provider that cannot pass all four in writing has told you enough.
The checklist
| # | Check | How to do it | Pass looks like |
|---|---|---|---|
| 1 | Named prescriber | Ask who will write the prescription | A full name and licence type |
| 2 | Licence in your state | Search your state medical or nursing board; the NPI registry confirms identity | Active licence, no discipline you are not told about |
| 3 | Real evaluation | Notice whether the intake can say no | Medical history, questions, some people declined |
| 4 | Named pharmacy | Ask for the pharmacy’s name and state | A specific facility, not “our network” |
| 5 | Pharmacy licence | Search the state board of pharmacy; 503B facilities appear on FDA’s outsourcing list | Active 503A licence or 503B registration |
| 6 | Substance status | Look it up on our status table | Approved product or Category 1 |
| 7 | Legal basis in writing | Ask the pharmacy what route it uses for this substance | A clear answer: approved component, USP, bulks list or Category 1 |
| 8 | Honest evidence claims | Read the marketing | Says what is unproven; no mouse data dressed as human results |
| 9 | Total price and terms | Ask for monthly total, renewal and cancellation terms | All in writing before you pay |
| 10 | No research-use language | Search the site for “research use” | Absent |
Check the substance before the provider
The best provider in the world cannot lawfully compound a substance that has no route. As of October 15, 2026, BPC-157, TB-500, CJC-1295, ipamorelin and AOD-9604 are in none of FDA’s categories, so check 7 should fail for them however polished the clinic. For NAD, glutathione and non-injectable GHK-Cu, Category 1 is the answer to expect. For tesamorelin, ask whether you will receive Egrifta WR or a compounded version. See which peptides can be compounded.
Red flags that end the conversation
- “For research use only” or “not for human consumption” anywhere on the site.
- Dosing calculators or reconstitution guides for unapproved peptides sold without a prescription.
- Claims that BPC-157 or TB-500 is “now legal” or “FDA-cleared”. Neither is, as of October 15, 2026.
- “FDA-approved pharmacy”. There is no such thing: pharmacies are state-licensed or FDA-registered; drugs are approved.
- A refusal to name the pharmacy.
Search FDA’s warning letters
FDA publishes its warning letters. In 2026 it warned at least eight peptide sellers, including five on August 24 — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides (example letter). Search the provider’s and the pharmacy’s names in FDA’s warning-letter database before you buy. Our research vs prescription peptides page lists all eight.
For pharmacy checks in more depth, see how to verify a compounding pharmacy.
October 2026: what changed
- April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
- July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
- October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.
For verification: add one check until the interim policy is public — if a provider cites a new FDA policy to justify a peptide, ask for the FDA document. As of October 15, 2026 the policy was under White House review and its text was not public.
Frequently asked questions
How do I check if a peptide clinic is legitimate?
Confirm a named clinician licensed in your state, a named pharmacy you can look up with your state board of pharmacy, a substance that is FDA-approved or in FDA’s Category 1, and no “research use only” wording. Get the pharmacy’s legal basis for compounding in writing.
How do I check a pharmacy’s licence?
Search the pharmacy’s name on your state board of pharmacy’s licence lookup, and on the board in the state where the pharmacy is located. FDA-registered 503B outsourcing facilities also appear on FDA’s list of registered facilities.
What if the clinic offers BPC-157?
As of October 15, 2026, BPC-157 has no established federal compounding route: it is not approved, not on the 503A bulks list and in no FDA category. Ask the clinic for the pharmacy’s legal basis in writing; there is no standard answer that satisfies it.
Is a provider with good reviews safe?
Reviews do not tell you whether a substance is lawful or how a vial was made. Run the ten checks on this page regardless of reviews, star ratings or social media following.
Sources
- FDA — Interim policy categories for 503A and 503B bulk drug substances (PDF, updated May 14, 2026) (read October 15, 2026)
- FDA — Certain bulk drug substances for use in compounding that may present significant safety risks (page current as of April 22, 2026) (read October 15, 2026)
- FDA — Bulk drug substances used in compounding under section 503A (page current as of May 14, 2026) (read October 15, 2026)
- FDA warning letter — Royal Peptides LLC, 734884 (August 24, 2026) (read October 15, 2026)
- FDA warning letter — Peptide Partners LLC, 735063 (August 24, 2026) (read October 15, 2026)
- OIRA (reginfo.gov) — Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94 (pending EO 12866 review) (read October 15, 2026)
- Reuters via Yahoo News — FDA takes step to change peptide compounding access (October 15, 2026) (read October 15, 2026)